Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

• Status: Withdrawn
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

This research study is a way of gaining new knowledge about a drug called olaparib in women who have either: 1)never received a PARP inhibitor before to treat ovarian cancer (group 1) or 2)participants who have received a PARP inhibitor before to treat ovarian cancer, with the exception of olaparib (group 2). PARP inhibitors are drugs tht prevent cancer cells from repairing their DNA. In this research study, we are looking to see how well the drug olaparib works in women who have never received a PARP inhibitor for recurrent ovarian cancer as well as those who have received a prior PARP inhibitor and whose cancer has re-grown after receiving that PARP inhibitor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Treatments: Olaparib; Poly(ADP-ribose) Polymerase Inhibitors

Criteria

Inclusion Criteria:

• Histologically confirmed ovarian, peritoneal or fallopian tube cancer that has recurred following a platinum-based regimen used at initial diagnosis

• Measurable disease

• Estimated life expectancy greater than 16 weeks

• Normal organ and marrow function

• Evidence of non-childbearing status for women of childbearing potential

• Able to swallow oral medication

Exclusion Criteria:

• Pregnant or breastfeeding

• Prior PARP inhibitor use for another cancer such as breast cancer

• Receiving any other study agents or any other anti-cancer treatment

• Known brain metastases

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• History of a different malignancy unless disease-free for at least 5 years

• Currently experiencing seizures or currently being treated with any anti-epileptic for seizures

• Human immunodeficiency virus (HIV) positive on combination antiretroviral therapy

• Presence of gastrointestinal disorders that, in the investigator's opinion, are likely to interfere with the absorption of olaparib, or with the patient's ability to take regular oral medication